

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	NO. CONFIRMATION NO.	
10/522,510	09/17/2005	Martin Gimmestad	BAFM0001-100	4461	
34132 7	590 04/17/2006		EXAMINER		
COZEN O'CONNOR, P.C. 1900 MARKET STREET			MEAH, MOHAMMAD Y		
	IIA, PA 19103-3508		ART UNIT	PAPER NUMBER	
	•		1652		
			DATE MAILED: 04/17/2000	,	

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Applica	tion No.	Applicant(s)	· · · · · · · · · · · · · · · · · · ·				
Office Action Summary		10/522	510	GIMMESTAD ET AL.					
		Examin	er	Art Unit					
			mad Meah	1652					
Period fo	The MAILING DATE of this commun	ication appears on t	he cover sheet with the	correspondence ad	ddress				
A SHO WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD F CHEVER IS LONGER, FROM THE M resions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this comm reperiod for reply is specified above, the maximum street or reply within the set or extended period for reply reply received by the Office later than three months a red patent term adjustment. See 37 CFR 1.704(b).	AILING DATE OF of 37 CFR 1.136(a). In no nunication. atutory period will apply and will, by statute, cause the a	THIS COMMUNICATIC event, however, may a reply be to will expire SIX (6) MONTHS from pplication to become ABANDON	N. imely filed in the mailing date of this c ED (35 U.S.C. § 133).					
Status									
1)⊠	Responsive to communication(s) file	ed on							
	•	2b)⊠ This action is	non-final.						
3)									
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims								
4)🖂	4)⊠ Claim(s) <u>1-26</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.								
5)	5) Claim(s) is/are allowed.								
6)□	6) Claim(s) is/are rejected.								
7)	7) Claim(s) is/are objected to.								
8)⊠	Claim(s) <u>1-26</u> are subject to restricti	on and/or election r	equirement.						
Applicati	on Papers								
9)[The specification is objected to by th	e Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
11)	The oath or declaration is objected to	b by the Examiner.	Note the attached Offic	e Action or form P	TO-152.				
Priority ι	ınder 35 U.S.C. § 119								
	Acknowledgment is made of a claim All b) Some * c) None of: 1. Certified copies of the priority 2. Certified copies of the priority	documents have b	een received.						
	3. Copies of the certified copies application from the Internation	onal Bureau (PCT R	ule 17.2(a)).		l Stage				
* 8	See the attached detailed Office action	on for a list of the ce	rtified copies not receiv	/ed.					
Attachmen	ıt(s)								
1) Notic	ce of References Cited (PTO-892)		4) Interview Summa						
3) Infor	ce of Draftsperson's Patent Drawing Review (F mation Disclosure Statement(s) (PTO-1449 or er No(s)/Mail Date		Paper No(s)/Mail 5) Notice of Informal 6) Other:		O-152)				

Application/Control Number: 10/522,510 Page 2

Art Unit: 1652

DETAILED ACTION

1. The claims 1-26 are pending in the instant office action.

Restriction

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-15, drawn to bacterial culture comprising mutant strain of P. fluorescens producing alginate.

Group II, claims 16-23, drawn to method of production of mutant strain of P. fluorescens producing alginate of claim I.

Group III. Claims 24-25, drawn to use of bacterial culture comprising mutant strain of P. fluorescens for the production of alginate.

Group IV. Claim 26, drawn to drawn to use of alginate in the production of food, drug, etc.

3. The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I, and groups II-IV do not share their technical feature because one Group involve product, bacteria, other Groups involve the method steps. Thus, while the products of

Application/Control Number: 10/522,510 Page 3

Art Unit: 1652

Groups I is affected by the method of group II, product of group I can be used in other methods having other technical features (such as protein preparation). Groups II-IV do not share same technical feature because they involve different method steps, use different products and produce different outcomes.

Furthermore, the technical feature linking group I-IV appears to be that they all relate to mutant strain of P. fluorescens producing alginate of group I. The mutant strain of P. fluorescens producing alginate group I does not constitute a "special technical feature" as defined by PCT Rule 13.2, because it does not claim a feature which defines a contribution over the prior art as mutant strain of P. fluorescens producing alginate is taught by Huisman et al. (US 2004/0014197 A1).

- 4. In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.
- 5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/522,510

Art Unit: 1652

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mohammad Meah whose telephone number is 571-272-1261. The examiner can normally be reached on 8:30-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Mohammad Younus Meah, PhD Examiner, Art Unit 1652 Recombinant Enzymes, 3C31 Remsen Bld 400 Dulany Street, Alexandria, VA 22314

Telephone: 517-272-1261

TEKCHAND SAIDHA